A Novel Monoclonal Antibody Induces Cancer Cell Apoptosis and Enhances the Activity of Chemotherapeutic Drugs |
Xu, Heng
(Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University)
Tian, Yan-Na (Jinfiniti Biosciences LLC) Dun, Bo-Ying (Jinfiniti Biosciences LLC) Liu, Hai-Tao (Jinfiniti Biosciences LLC) Dong, Guang-Kuo (Jinfiniti Biosciences LLC) Wang, Jin-Hua (Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Georgia Regents University) Lu, Shang-Su (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) Chen, Bo (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) She, Jin-Xiong (Institute of Translational Medicine, School of Pharmaceutical Sciences, Nanjing Tech University) |
1 | Attard G, Kitzen J, Blagden S, et al (2007). A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer, 97, 1338-43. DOI |
2 | Chao MP, Alizadeh AA, Tang C, et al (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142, 699-713. DOI |
3 | Crescence L, Beraud E, Sbarra V, et al (2012). Targeting a novel onco-glycoprotein antigen at tumoral pancreatic cell surface by mAb16D10 induces cell death. J Immunol, 189, 3386-96. DOI |
4 | de Weers M, Tai YT, van der Veer MS, et al (2011). Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol, 186, 1840-8. DOI |
5 | Estevez LG, Martin M, Alba E, et al (2007). Current controversies in the management of early breast cancer. Clin Transl Oncol, 9, 375-84. DOI |
6 | Gallamini A, Zaja F, Patti C, et al (2007). Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood, 110, 2316-23. DOI |
7 | Giansanti V, Torriglia A, Scovassi AI (2011). Conversation between apoptosis and autophagy:"Is it your turn or mine?". Apoptosis, 16, 321-33. DOI |
8 | Gorter A, Meri S (1999). Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today, 20, 576-82. DOI |
9 | Grillo-Lopez AJ, Hedrick E, Rashford M, et al (2002). Rituximab: ongoing and future clinical development. Paper presented at: Seminars in oncology (Elsevier). |
10 | Jiang L, Hao JL, Jin ML, et al (2013). Effect of embelin on TRAIL receptor 2 mAb-induced apoptosis of TRAIL-resistant A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev, 14, 6115-20. 과학기술학회마을 DOI ScienceOn |
11 | Loo D, Pryer N, Young P, et al (2007). The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther, 6, 856-65. |
12 | Majno G, Joris I (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol, 146, 3. |
13 | Maloney D (2003). Rituximab for follicular lymphoma. Curr Hematol Rep, 2, 13. |
14 | Parren PW, van de Winkel JG (2008). An integrated science-based approach to drug development. Curr Opin Immunol, 20, 426-30. DOI |
15 | Saltz LB, Meropol NJ, Loehrer PJ, et al (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 22, 1201-8. DOI ScienceOn |
16 | Scott AM, Wolchok JD, Old LJ (2012). Antibody therapy of cancer. Nat Rev Cancer, 12, 278-87. DOI ScienceOn |
17 | Xu G, Wen X, Hong Y, et al (2011). An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human glioma cells. Int Immunopharmacol, 11, 1844-9. DOI |
18 | Willingham SB, Volkmer JP, Gentles AJ, et al (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA, 109, 6662-7. DOI |
19 | Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science, 281, 1312-6. DOI ScienceOn |
20 | Weiner LM, Murray JC, Shuptrine CW (2012). Antibody-based immunotherapy of cancer. Cell, 148, 1081-4. DOI |
21 | Yip YL, Ward RL (2002). Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immun, 50, 569-87. DOI |
22 | Zhang G, Zhang H, Wang Q, et al (2010). Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker. Proc Natl Acad Sci USA, 107, 732-7 DOI |
23 | Hernandez AM, Rodriguez N, Gonzalez JE, et al (2011). Anti-NeuGcGM3 antibodies, actively elicited by idiotypic vaccination in nonsmall cell lung cancer patients, induce tumor cell death by an oncosis-like mechanism. J Immunol, 186, 3735-44. DOI |
24 | Tyas L, Brophy VA, Pope A, et al (2000). Rapid caspase-3 activation during apoptosis revealed using fluorescence-resonance energy transfer. EMBO Rep, 1, 266-70. DOI |